Satellos Bioscience Inc.

TSX:MSCL Stock Report

Market Cap: CA$100.2m

Satellos Bioscience Management

Management criteria checks 1/4

Satellos Bioscience's CEO is Frank Gleeson, appointed in Mar 2018, has a tenure of 6.75 years. total yearly compensation is CA$1.93M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 3.49% of the company’s shares, worth CA$3.50M. The average tenure of the management team and the board of directors is 1.6 years and 3 years respectively.

Key information

Frank Gleeson

Chief executive officer

CA$1.9m

Total compensation

CEO salary percentage20.7%
CEO tenure6.8yrs
CEO ownership3.5%
Management average tenure1.6yrs
Board average tenure3yrs

Recent management updates

Recent updates

Is Satellos Bioscience (TSE:MSCL) In A Good Position To Deliver On Growth Plans?

Oct 07
Is Satellos Bioscience (TSE:MSCL) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Satellos Bioscience (TSE:MSCL) Will Use Its Cash Wisely

Apr 11
We're Hopeful That Satellos Bioscience (TSE:MSCL) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Satellos Bioscience's (CVE:MSCL) Cash Burn Situation

Dec 22
Here's Why We're Not Too Worried About Satellos Bioscience's (CVE:MSCL) Cash Burn Situation

Will Satellos Bioscience (CVE:MSCL) Spend Its Cash Wisely?

Apr 08
Will Satellos Bioscience (CVE:MSCL) Spend Its Cash Wisely?

CEO Compensation Analysis

How has Frank Gleeson's remuneration changed compared to Satellos Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$29m

Jun 30 2024n/an/a

-CA$23m

Mar 31 2024n/an/a

-CA$21m

Dec 31 2023CA$2mCA$398k

-CA$16m

Sep 30 2023n/an/a

-CA$14m

Jun 30 2023n/an/a

-CA$13m

Mar 31 2023n/an/a

-CA$11m

Dec 31 2022CA$338kCA$260k

-CA$11m

Sep 30 2022n/an/a

-CA$9m

Jun 30 2022n/an/a

-CA$18m

Mar 31 2022n/an/a

-CA$17m

Dec 31 2021CA$1mCA$226k

-CA$16m

Sep 30 2021n/an/a

-CA$13m

Jun 30 2021n/an/a

-CA$2m

Mar 31 2021n/an/a

-CA$2m

Dec 31 2020CA$192kCA$192k

-CA$2m

Dec 31 2019CA$180kCA$180k

-CA$2m

Compensation vs Market: Frank's total compensation ($USD1.34M) is above average for companies of similar size in the Canadian market ($USD163.24K).

Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.

CEO

Frank Gleeson (69 yo)

6.8yrs

Tenure

CA$1,926,547

Compensation

Mr. Francis Gleeson, also known as Frank, B.B.A., M.B.A., is a Co-Founder of Satellos Bioscience Inc. He serves as Chief Executive Officer of Satellos Bioscience Inc. since March 2018. He serves as Directo...

Leadership Team

NamePositionTenureCompensationOwnership
Francis Gleeson
Co-Founder6.8yrsCA$1.93m3.49%
CA$ 3.5m
Elizabeth Williams
CFO & Corporate Secretary1.3yrsCA$741.42k0.035%
CA$ 35.2k
Philip Lambert
Chief Scientific Officer1.9yrsCA$1.45mno data
William Jarosz
Executive Director3.3yrsCA$216.74k1.5%
CA$ 1.5m
Warren Whitehead
Head of Corporate Strategy1.3yrsCA$444.38kno data
Michael Cross
Chief Business Officer1.3yrsCA$745.80k0.0037%
CA$ 3.7k
Michael Rudnicki
Co-Founder & Chief Discovery Officerno dataCA$120.00k2.72%
CA$ 2.7m
J. Hall
Senior Vice President of Finance & Administration3.3yrsno data0.070%
CA$ 70.4k
Michael Liggett
Strategic Advisor3.3yrsCA$44.48kno data
Desiree Chan
Chief of Staffno datano datano data
Courtney Wells
Senior Vice President of Clinical Development Operations1.1yrsno datano data
Ryan Mitchell
Senior Vice President of Medical & Scientific Affairsless than a yearno datano data

1.6yrs

Average Tenure

63yo

Average Age

Experienced Management: MSCL's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Francis Gleeson
Co-Founder12.4yrsCA$1.93m3.49%
CA$ 3.5m
William Jarosz
Executive Director3.3yrsCA$216.74k1.5%
CA$ 1.5m
Franklin Berger
Independent Director1.5yrsCA$47.41k6.92%
CA$ 6.9m
Geoff MacKay
Independent Chairman of the Board of Directors6.4yrsCA$87.84k0.22%
CA$ 223.9k
William McVicar
Independent Director3.3yrsCA$68.27k0.022%
CA$ 22.0k
Brian Bloom
Independent Director6.8yrsno data1.3%
CA$ 1.3m
Adam Mostafa
Independent Director3yrsCA$93.58kno data
Jordan Dubow
Chair of Clinical Advisory Board & Chief Medical Advisorless than a yearno datano data
Ronald Cohn
Member of Clinical Advisory Boardless than a yearno datano data
Rima Al-awar
Independent Director3yrsCA$69.28kno data
Nicholas Johnson
Member of Clinical Advisory Boardless than a yearno datano data
Perry Shieh
Member of Clinical Advisory Boardless than a yearno datano data

3.0yrs

Average Tenure

62yo

Average Age

Experienced Board: MSCL's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 05:55
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Satellos Bioscience Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tania Armstrong-WhitworthCanaccord Genuity
Yu HeH.C. Wainwright & Co.
David BautzZacks Small-Cap Research